DADC
SCMP

D.A. Davidson & Co’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

D.A. Davidson & Co’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,340
Closed -$31K – 2577
2016
Q4 		$31K Buy
+2,340
New +$32.6K ﹤0.01% 1784

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.A. Davidson & Co's SCMP Position: Q1 2017 in Review

D.A. Davidson & Co sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2017, closing a stake of 2,340 shares — an estimated $31K sold.

D.A. Davidson & Co first reported a position in SCMP in Q4 2016 and held it in 1 quarter. The position peaked at $31K in Q4 2016. 167 funds tracked by Wall St. Rank hold SCMP as of Q1 2017.

  • D.A. Davidson & Co reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 2,340 Sucampo Pharmaceuticals, Inc. shares in Q1 2017, an estimated $31K.
  • D.A. Davidson & Co first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • D.A. Davidson & Co's Sucampo Pharmaceuticals, Inc. position peaked at $31K in Q4 2016.
  • 167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2017.

Based on D.A. Davidson & Co's 13F filing for Q1 2017, filed 12 May 2017.